As concern over fast-spreading coronavirus variants continue among even highly-vaccinated populations, an Israel-based pharmaceutical company is hoping that its oral drug candidate will help get COVID-19 patients off oxygen support more quickly.

RedHill Biopharma says it is only weeks away from a make or break point to show the effectiveness of its drug candidate, opaganib, in treating patients with severe breathing-related symptoms caused by the coronavirus.

“Delta variants are scaring everyone, rightfully so, and more and more people are nervous about what’s going to happen. Vaccines are being less and less effective than we thought as the rate of infection is becoming higher and higher,” Guy Goldberg, Chief Business Officer at RedHill Biopharma told The Algemeiner during an interview.

“It is not just the question of people who are unvaccinated. This is an emerging story, and one that threatens to bring the whole world back to square one,” he said. “The need for therapeutics is as strong now as it ever has been during the pandemic, and there is not enough innovation out there.”... Read More: Algemeiner